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Background: There exist multiple approaches to CHD risk stratification but their comparative cost and effectiveness is unknown.
Methods: We compared five strategies for identifying and treating risk factors among men 35-80 years of age and women 45-80 years of age: 1) 
a “treat all” approach in which the entire population received high-dose statins and low-dose aspirin regardless of (FRS) or baseline LDL level 2) 
an Adult Treatment Panel (ATP) III approach, in which statin initiation and dose was based on both baseline FRS and LDL 3) a SHAPE approach in 
which each patient underwent coronary artery calcium scanning (CAC) which determined therapy 4) a Texas Bill approach, in which only patients 
with FRS > 10% undergo CAC to determine treatment 5) a JUPITER approach in which all persons with LDL < 130 mg/dl and CRP > 2 mg/L receive 
40mg of rosuvastatin. All strategies except treat all included low dose aspirin for those with FRS > 10%, and were compared to 2011 status quo use 
of statins. Outcomes evaluated were incidence of, new CHD, fatal and non-fatal MI, all cause mortality, costs, radiation induced malignancies, and 
quality adjusted life years (QALY) gained. Microsimulations using a Markov model (N=1 million for each gender) were performed over the period of 
2011-2040.
Results: All strategies were less costly and more effective than the status quo. “Treat all” was the most effective strategy for both men and women 
realizing 187,860 and 68,350 QALYs respectively compared to status quo. For men the number of MI prevented ranged from 75,000 in Texas to 
160,000 in “treat all”, and while SHAPE prevented more MI than ATP III, it led to 206 imaging related malignancies. For women, MI prevented ranged 
from 5,848 in JUPITER to 39,400 in “treat all”. The ATP III based approach placed the smallest proportion on statins (28%). For men the “treat 
all” approach was the least costly, while for women SHAPE was less costly than treat all, but the incremental cost-effectiveness ratio for treat all 
compared to SHAPE was only $2,425/QALY gained.
Conclusions: While CAC, CRP, and FRS based approaches to CHD risk stratification are all cost effective, an approach treating all persons 
regardless of LDL with high dose statins appears most cost effective.
